Hepatocellular adenoma medical therapy
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD[2]
Overview
Overview
There is no specific medical therapy for hepatocellular adenoma. The wait-and-watch policy is recommended for hepatocellular adenomas < 5 cm following cessation of offending drugs (OCPs) with no further growth detected. An annual follow-up with MRI or ultrasound is scheduled for female patients untill menopause.
Medical Therapy
Medical Therapy
- There is no specific medical therapy for hepatocellular adenoma.[1][2]
- Historically, hepatocellular adenomas were treated with a wait-and-watch policy, with surgical intervention recommended for larger (> 5 cm) tumors.
- In asymptomatic female patients, the first step is to stop the offending drug (such as OCPs) and follow-up to document any change in the size of the tumor.
- The wait-and-watch policy is recommended when the tumor is < 5 cm in size or when it has regressed (to < 5 cm) following cessation of the offending drug (OCPs) with no further growth detected.[3]
- An annual follow-up with MRI or ultrasound is scheduled for female patients untill menopause.[4][5][6][7][8][9][10]
References
References
- ↑ Toso C, Majno P, Andres A, Rubbia-Brandt L, Berney T, Buhler L, Morel P, Mentha G (2005). “Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors”. World J Gastroenterol. 11 (36): 5691–5. PMID 16237767.Full text
- ↑ Ault GT, Wren SM, Ralls PW, Reynolds TB, Stain SC (1996). “Selective management of hepatic adenomas”. Am Surg. 62 (10): 825–9. PMID 8813164.
- ↑ Maarten G. Thomeer, Mirelle Broker, Joanne Verheij, Michael Doukas, Turkan Terkivatan, Diederick Bijdevaate, Robert A. De Man, Adriaan Moelker & Jan N. IJzermans (2016). “Hepatocellular adenoma: when and how to treat? Update of current evidence”. Therapeutic advances in gastroenterology. 9 (6): 898–912. doi:10.1177/1756283X16663882. PMID 27803743. Unknown parameter
|month=ignored (help) - ↑ Barthelmes L, Tait IS (2005). “Liver cell adenoma and liver cell adenomatosis”. HPB (Oxford). 7 (3): 186–96. doi:10.1080/13651820510028954. PMC 2023950. PMID 18333188.
- ↑ A. F. Mariani, A. S. Livingstone, R. V. Jr Pereiras, P. E. van Zuiden & E. R. Schiff (1979). “Progressive enlargement of an hepatic cell adenoma”. Gastroenterology. 77 (6): 1319–1325. PMID 499719. Unknown parameter
|month=ignored (help) - ↑ P. H. Andersen & J. T. Packer (1976). “Hepatic adenoma. Observations after estrogen withdrawal”. Archives of surgery (Chicago, Ill. : 1960). 111 (8): 898–900. PMID 182106. Unknown parameter
|month=ignored (help) - ↑ S. Kay (1977). “Nine year follow-up of a case of benign liver cell adenoma related to oral contraceptives”. Cancer. 40 (4): 1759–1760. PMID 198104. Unknown parameter
|month=ignored (help) - ↑ P. Aseni, C. V. Sansalone, C. Sammartino, F. D. Benedetto, G. Carrafiello, A. Giacomoni, C. Osio, M. Vertemati & D. Forti (2001). “Rapid disappearance of hepatic adenoma after contraceptive withdrawal”. Journal of clinical gastroenterology. 33 (3): 234–236. PMID 11500616. Unknown parameter
|month=ignored (help) - ↑ H. Buhler, M. Pirovino, A. Akobiantz, J. Altorfer, M. Weitzel, E. Maranta & M. Schmid (1982). “Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use”. Gastroenterology. 82 (4): 775–782. PMID 6277724. Unknown parameter
|month=ignored (help) - ↑ B. Heeringa & A. Sardi (2001). “Bleeding hepatic adenoma: expectant treatment to limit the extent of liver resection”. The American surgeon. 67 (10): 927–929. PMID 11603546. Unknown parameter
|month=ignored (help)
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH